HUP0303279A3 - Indolylopyrrolocarbazoles sugar derivatives as topoisomerase inhibitors and pharmaceutical compositions containing them - Google Patents

Indolylopyrrolocarbazoles sugar derivatives as topoisomerase inhibitors and pharmaceutical compositions containing them

Info

Publication number
HUP0303279A3
HUP0303279A3 HU0303279A HUP0303279A HUP0303279A3 HU P0303279 A3 HUP0303279 A3 HU P0303279A3 HU 0303279 A HU0303279 A HU 0303279A HU P0303279 A HUP0303279 A HU P0303279A HU P0303279 A3 HUP0303279 A3 HU P0303279A3
Authority
HU
Hungary
Prior art keywords
indolylopyrrolocarbazoles
pharmaceutical compositions
compositions containing
topoisomerase inhibitors
sugar derivatives
Prior art date
Application number
HU0303279A
Other languages
English (en)
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of HUP0303279A2 publication Critical patent/HUP0303279A2/hu
Publication of HUP0303279A3 publication Critical patent/HUP0303279A3/hu

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H9/00Compounds containing a hetero ring sharing at least two hetero atoms with a saccharide radical
    • C07H9/06Compounds containing a hetero ring sharing at least two hetero atoms with a saccharide radical the hetero ring containing nitrogen as ring hetero atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/23Heterocyclic radicals containing two or more heterocyclic rings condensed among themselves or condensed with a common carbocyclic ring system, not provided for in groups C07H19/14 - C07H19/22
HU0303279A 2000-10-06 2001-10-01 Indolylopyrrolocarbazoles sugar derivatives as topoisomerase inhibitors and pharmaceutical compositions containing them HUP0303279A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23872600P 2000-10-06 2000-10-06
PCT/US2001/030640 WO2002030941A2 (en) 2000-10-06 2001-10-01 Topoisomerase inhibitors

Publications (2)

Publication Number Publication Date
HUP0303279A2 HUP0303279A2 (hu) 2004-01-28
HUP0303279A3 true HUP0303279A3 (en) 2004-11-29

Family

ID=22899064

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0303279A HUP0303279A3 (en) 2000-10-06 2001-10-01 Indolylopyrrolocarbazoles sugar derivatives as topoisomerase inhibitors and pharmaceutical compositions containing them

Country Status (7)

Country Link
US (1) US6677450B2 (hu)
EP (1) EP1326874A2 (hu)
JP (1) JP2004523478A (hu)
AU (1) AU2001296435A1 (hu)
CA (1) CA2424971A1 (hu)
HU (1) HUP0303279A3 (hu)
WO (1) WO2002030941A2 (hu)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004025726B4 (de) * 2004-05-26 2006-07-06 Roder, Hanno, Dr. Verwendung eines spezifischen K252a-Derivats zur Verhinderung oder Behandlung der Alzheimerschen Krankheit
JP2008504292A (ja) 2004-06-24 2008-02-14 ノバルティス ヴァクシンズ アンド ダイアグノスティクス, インコーポレイテッド 免疫増強用の化合物
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
AR060358A1 (es) 2006-04-06 2008-06-11 Novartis Vaccines & Diagnostic Quinazolinas para la inhibicion de pdk 1
WO2008076394A1 (en) * 2006-12-14 2008-06-26 Tautatis, Inc. Compositions and methods for the treatment of cancer
JP2011506560A (ja) 2007-12-20 2011-03-03 ノバルティス アーゲー Pi3キナーゼ阻害剤として用いられるチアゾール誘導体
ES2326459B1 (es) * 2008-04-08 2010-05-28 Universidad De Oviedo Indolocarbazoles glicosilados, su procedimiento de obtencion y sus usos.
US8293753B2 (en) 2009-07-02 2012-10-23 Novartis Ag Substituted 2-carboxamide cycloamino ureas
AR082418A1 (es) 2010-08-02 2012-12-05 Novartis Ag Formas cristalinas de 1-(4-metil-5-[2-(2,2,2-trifluoro-1,1-dimetil-etil)-piridin-4-il]-tiazol-2-il)-amida de 2-amida del acido (s)-pirrolidin-1,2-dicarboxilico
US8987257B2 (en) 2011-01-31 2015-03-24 Novartis Ag Heterocyclic derivatives
EP2771342B1 (en) 2011-10-28 2016-05-18 Novartis AG Purine derivatives and their use in the treatment of disease
US10213432B2 (en) 2012-05-16 2019-02-26 Novartis Ag Dosage regimen for a PI-3 kinase inhibitor
PL3076969T3 (pl) 2013-12-06 2022-01-17 Novartis Ag Schemat dawkowania selektywnego inhibitora 3-kinazy fosfatydynozytolu alfa-izoformy
CN104031052B (zh) * 2014-05-20 2016-06-08 中国科学院南海海洋研究所 抗生素Indimicins A–E及其制备方法和在制备抗肿瘤药物中的应用
CA3002954A1 (en) 2015-11-02 2017-05-11 Novartis Ag Dosage regimen for a phosphatidylinositol 3-kinase inhibitor
WO2018060833A1 (en) 2016-09-27 2018-04-05 Novartis Ag Dosage regimen for alpha-isoform selective phosphatidylinositol 3-kinase inhibitor alpelisib

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4487925A (en) 1983-01-28 1984-12-11 Bristol-Myers Company Rebeccamycin and process for its preparation
US4552842A (en) 1983-01-28 1985-11-12 Bristol-Myers Company Process for producing rebeccamycin
US4567143A (en) 1984-09-04 1986-01-28 Bristol-Myers Company Process for preparing 4'-deschlororebeccamycin
US4785085A (en) 1986-11-21 1988-11-15 Bristol-Myers Company Rebeccamycin analogs
JP2766360B2 (ja) * 1988-02-04 1998-06-18 協和醗酵工業株式会社 スタウロスポリン誘導体
DE3924538A1 (de) 1989-07-25 1991-01-31 Goedecke Ag Indolocarbazol und dessen verwendung
US5618809A (en) * 1989-12-14 1997-04-08 Schering Corporation Indolocarbazoles from saccharothrix aerocolonigenes copiosa subsp. nov SCC 1951 ATCC 53856
IL97233A (en) 1990-03-06 1995-03-30 Bristol Myers Squibb Co Analogs of rabamycin, their manufacture and pharmaceutical preparations containing them
US5478813A (en) 1990-05-11 1995-12-26 Banyu Pharmaceutical Co., Ltd. Antitumor substance BE-13793C derivatives
US5668271A (en) 1991-11-29 1997-09-16 Banyu Pharmaceutical Co., Ltd. Indolopyrrolocarbazole derivatives
US5589365A (en) 1991-11-29 1996-12-31 Banyu Pharmaceutical Co., Ltd. Process for producing glycosylated indolopyrrolocarbazole derivatives by culturing certain microorganisms
NZ245203A (en) 1991-11-29 1997-07-27 Banyu Pharma Co Ltd 5h-indolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7(6h)-dione derivatives substituted in position-13 by a pentose or hexose group; corresponding indolo-furano(anhydride)intermediates
DE69331228D1 (en) * 1992-09-21 2002-01-10 Kyowa Hakko Kogyo Kk Heilmittel für thrombozytopenia
FR2696465B1 (fr) 1992-10-02 1994-12-23 Adir Nouveaux dérivés d'ellipticine, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent.
JP3603322B2 (ja) 1992-12-14 2004-12-22 萬有製薬株式会社 インドロピロロカルバゾール誘導体の製造法
US5468872A (en) 1993-09-16 1995-11-21 Cephalon, Inc. K-252a functional derivatives potentiate neurotrophin-3 for the treatment of neurological disorders
WO1995030682A1 (fr) 1994-05-09 1995-11-16 Banyu Pharmaceutical Co., Ltd. Derive d'indolopyrolocarbazole antitumoral
WO1996004293A1 (fr) 1994-08-02 1996-02-15 Banyu Pharmaceutical Co., Ltd. Indolopyrrolocarbazoles antitumoraux
US5475110A (en) 1994-10-14 1995-12-12 Cephalon, Inc. Fused Pyrrolocarbazoles
US5705511A (en) 1994-10-14 1998-01-06 Cephalon, Inc. Fused pyrrolocarbazoles
WO1997007081A2 (en) * 1995-08-11 1997-02-27 Yale University Glycosylated indolocarbazole synthesis
BR9711306A (pt) 1996-08-22 1999-08-17 Bristol Myers Squibb Co Amino a-Úcar citotÄxico e derivados de a-Úcar correlatos de indolopirrolocarbazÄis
CO4940430A1 (es) * 1997-07-07 2000-07-24 Novartis Ag Compuestos policiclicos que contienen estaurosporina hidrogenada con propiedades farmacologicas convenientes y un efecto inhibidor sobre el crecimiento de las celulas tumorales
FR2801054B1 (fr) 1999-11-17 2003-06-13 Adir Nouveaux derives de 12,13-(pyranosyl)-indolo[2,3-a]pyrrolo [3,4-c]carbazole et 12,13-(pyranosyl)-furo[3,4-c]indolo [2,3-a]carbazole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Also Published As

Publication number Publication date
EP1326874A2 (en) 2003-07-16
CA2424971A1 (en) 2002-04-18
US6677450B2 (en) 2004-01-13
WO2002030941A2 (en) 2002-04-18
JP2004523478A (ja) 2004-08-05
AU2001296435A1 (en) 2002-04-22
HUP0303279A2 (hu) 2004-01-28
WO2002030941A3 (en) 2002-10-03
US20020107237A1 (en) 2002-08-08

Similar Documents

Publication Publication Date Title
HUP0500173A3 (en) Alpha-sulphonamido-acetamide derivatives as beta-amyloid inhibitors and pharmaceutical compositions containing them
HUP0302485A3 (en) Arylmethylamine derivatives for use as tryptase inhibitors and pharmaceutical compositions containing them
HUP0400451A3 (en) Pyrrole derivatives and pharmaceutical compositions containing them
IL165119A0 (en) C-aryl glucoside derivatives and pharmaceutical compositions containing the same
HUP0302412A3 (en) Betha-carboline derivatives useful as inhibitors of phosphodiesterase and pharmaceutical compositions containing the same
IL152490A0 (en) Pyridine derivatives and pharmaceutical compositions containing the same
IL148806A0 (en) C-aryl glucoside derivatives and pharmaceutical compositions containing the same
IL151209A0 (en) Pharmaceutical compositions containing 3-aminoazetidine derivatives, novel derivatives and their preparation
IL150734A0 (en) Azaindole derivatives and pharmaceutical compositions containing the same
HUP0301178A3 (en) Glucopyranosyloxybenzylbenzene derivatives and pharmaceutical compositions containing the same
HUP0300565A3 (en) 8-quinolinxanthine and 8-isoquinolinxanthine derivatives as pde 5 inhibitors, their use, process for their preparation and pharmaceutical compositions containing them
HUP0400837A3 (en) 2-phenyl-thiazole derivatives, their use and pharmaceutical compositions containing them
HUP0204474A3 (en) 1h-imidazopyridine derivatives, pharmaceutical compositions containing them and their use
HUP0303279A3 (en) Indolylopyrrolocarbazoles sugar derivatives as topoisomerase inhibitors and pharmaceutical compositions containing them
HUP0203288A3 (en) Pyrrole derivatives as phosphodiesterase vii inhibitors, pharmaceutical compositions containing them and their use
HUP0400011A3 (en) Dihydro isoquinoline derivatives as phosphodiesterase inhibitors and pharmaceutical compositions containing them
HUP0203245A3 (en) Imidazopyridine derivatives as phosphodiesterase vii inhibitors and pharmaceutical compositions containing them
HUP0001632A3 (en) Pharmaceutical compositions comprising selective phosphodiestherase inhibitors
HUP0301713A3 (en) Pharmaceutical compositions containing propenone derivatives and their use
HUP0303184A3 (en) Substituted c-cyclohexylmethylamine derivatives and pharmaceutical compositions containing them
IL176077A0 (en) 1-n-phenyl-amino-1h-imidazole derivatives and pharmaceutical compositions containing them
IL151912A0 (en) Pyrolidine derivatives, their preparation and pharmaceutical compositions containing them
PL356911A1 (en) Novel heterocyclic derivatives, preparation method and pharmaceutical compositions containing same
HUP0303204A3 (en) 1-methylcarbapenem derivatives and pharmaceutical compositions containing them
IL151715A0 (en) N-deacetylthiocolchicine derivatives and pharmaceutical compositions containing them